



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

**AMENDMENT UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE –  
EXAMINING GROUP 1642**

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

PATENT  
Attorney Docket No.: 015280-315100US  
Client Ref. No.: E-094-97/0

On 21 July 2005

TOWNSEND and TOWNSEND and CREW LLP

By: Melinda C. Daffin

**Corres. and Mail  
BOX AF**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

CHANDRASEKHARAPPA et al.

Application No.: 09/380,337

Filed: March 6, 2000

For: MENI, THE GENE ASSOCIATED  
WITH MULTIPLE ENDOCRINE  
NEOPLASIA TYPE 1, MENIN  
POLYPEPTIDES AND USES THEREOF

Customer No.: 20350

Confirmation No. 2491

Examiner: Ungar, Susan

Technology Center/Art Unit: 1642

**AMENDMENT UNDER 37 CFR 1.116  
EXPEDITED PROCEDURE EXAMINING  
GROUP 1642**

**Mail Stop AF**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Final Office Action mailed February 24, 2005 on the above-referenced application, please enter the following amendments and remarks. Enclosed herewith is petition with fee authorization to extend the time for response for two months and a Notice of Appeal.

**Amendments to the Claims** are reflected in the listing of claims that begins on page 2 of this paper.

**Remarks** begin on page 6 of this paper.